LymphActivist's Site
Dedicated to Lymphedema Patients and the Therapists Who Treat Them
LymphActivist's Site
Dedicated to Lymphedema Patients and the Therapists Who Treat Them
Efficacy of Lymphedema Treatment Protocols
Comments on Technology Assessment "Diagnosis and Treatment of Secondary Lymphedema".
Robert Weiss, MS, Lymphedema Patient Advocate
General Observations
The Many Faces of Lymphedema
Technology Assessments and Systematic Reviews
Randomized Clinical Trials Document Efficacy of Treatment Protocols
The following randomized clinical trials RCTs have been accepted for review by one or another of the systematic reviews listed above. There is credible evidence to show that every manual modality can benefit some population subset. Shown on the following table are the lead author and date of the RCT, the systematic review which used the RCT, characteristics of the trial cohort, modalities employed, summary results in terms of edema reduction and comments on the length of the trial or follow-up.
Reference |
Study* |
Population** |
Modalities*** |
Reduction† |
Comments |
Andersen 2000 |
TBCKF |
42-38 BCRL |
CGE/CGE+MLD |
60%/48% NS |
3 Mos. |
Badger 2000 |
BCF |
83 Upper & Lower |
CB+CG/CG |
31%/16% |
24 Wks. |
Barclay 2006 |
F |
BCRL |
Aromatherapy |
None |
|
Bertelli 1991 |
TEKMF |
60 BCRL ?c?10cm |
CG/ CG+ESLD |
17-21/16-17% |
2-6 Mo. |
Bertelli 1992 |
EM |
120 BCRL?c?10cm |
CG, IPC, ESLD |
15/13% |
2/6 Mo. |
Boris 1998 |
C |
128 LLLE |
IPC/No IPC |
43%/3% GLE |
Genital LE |
Carati 2003 |
TF |
64 BCRL |
LLLT/Placebo |
-90/+32 mL |
3 Mo. |
Didem 2005 |
THF |
53 BCRL for 3 Yr. |
CDT+HT |
56% |
Short Term |
Dini 1998 |
TCEHKF |
80 BCRL < 1 Yr. |
IPC |
11% |
Short Term |
Földi 1996 |
C |
150 BCRL+RC |
CDT |
Reduced DLA |
2 Yr. |
Hamner 2007 |
H |
135 BCRL |
CDT |
42% |
Short Term |
Hayes 2008 |
T |
32 BCRL |
E |
<1% |
3 Mo. |
Hornsby 1995 |
BCK |
25 |
SLD, E/+ CG |
36%, 86% |
16 Wk. |
Jahr 2008 |
T |
21 BCRL |
MLD+DO/MLD |
-16/+13mL |
Breast LE |
Jeffs 2006 |
H |
74 BCRL |
CDT |
5 to18% |
1 Yr. |
Johansson 1998 |
TCKF |
28+12/12 BCRL |
CG+SPC/MLD |
7%+ 7%/15% |
2.5 Yr. |
Johansson 1999 |
C |
38 BCRL |
CB\CB+MLD/CB |
26%\11/4% |
Short Term |
Kaviani 2006 |
TF |
8 BCRL |
LLLT/Sham |
Favors LLLT |
22 Wk. |
Kessler 2003 |
T |
21 Hindfoot Surgery |
E+MLD/E |
6%/0% |
|
Koul 2007 |
H |
138 BCRL |
CDT, MLD, HT |
-56, 41, 24% |
1 Yr. |
Kozanoglu 2009 |
T |
47 BCRL |
IPC+E/LLLT+E |
LLLT fav. LT |
12 Mo. |
Maiya 2008 |
T |
20 BCRL |
LLLT+E/CG+E |
|
10 Days |
McKenzie 2003 |
TCF |
14 BCRL |
E |
Nil |
2 Mo. |
McNeely 2004 |
TCF |
50 BCRL |
MLD+CB/CB |
46%/16% |
1 Mo. |
Radakovic 1998 |
T |
36 BCRL |
MLD/IPC |
0.9/2.24cm |
Short Term |
Shaw 2007 |
T |
21 BCRL |
WR/CG |
7% |
12 Wk. |
Shaw 2007 |
T |
51 BCRL Obese |
WR+CB+CG/CG |
WL—>Red |
24 Wk. |
Sitzia 2002 |
TF |
28 BCRL |
CB\MLD/SLD |
34/22% |
2 WK. |
Szuba 2002-1 |
TCF |
23 BCRL 12 Yrs. |
CDT+IPC/CDT |
30%/27% |
40 Days. |
Szuba 2002-2 |
TCF |
25 BCRL 9.5 Yrs. |
CDT+IPC/CDT |
90/33mL |
6 Mo. |
Vignes 2006 |
H |
357 BCRL |
CDT |
404 mL |
Short Term |
Vignes 2007 |
H |
356 BCRL |
CDT |
67% |
1 Yr. |
Wilburn 2006 |
TH |
10 BCRL 3-24 Yrs. |
SM/IPC |
+52/-208 mL |
42 Days |
Williams 2002 |
TCF |
29 BCRL |
MLD+SLD |
71/30 mL |
12 Wk. |
* The review or systematic study which identified the RCT: C=CHBRP 2005; Erickson 2001; H=Hayes 2008; K=Kligman 2003; M= Megens 1998; T=Technology Assessment-McMasters;
** BCRL=breast cancer-related lymphedema; LLLE=lower-limb lymphedema; RC=recurrent cellulitis
*** CB=compression bandaging; CDT=complex decongestive therapy; CG=compression garment; CGE=compression garment plus exercise; DO=Deep Oscillation; E=exercise; ESLD=electrically-stimulated lymph drainage; HT=home therapy; IPC=intermittent pneumatic compression; MLD=manual lymph drainage; SM=simple massage; SP=standard physiotherapy; WR=weight reduction
† DLA=Dermatolymphangioadenitis; GLE=genital lymphedema; NS=not significant
Cohort Studies Show Efficacy of Combined Decongestive Therapy
Study |
No. |
Measure |
Mean Decrease |
CDT Modalities |
Boris 1997 |
119 |
∆ Volume |
-63 to -69% |
MLD, CB, Exer., CG |
Bunce 1994 |
25 |
∆ Volume |
-50% |
MLD, CB, CG, Exer. |
Casley-Smith 1992 |
200 |
∆ Volume |
-60 to -103% |
MLD, CB, CG, Exer. |
Ferrandez 1992 |
102 |
∆ Circumference |
-40 to -60% |
MLD, CB, IPC |
Földi 1989 |
399 |
∆ Volume |
-54% |
MLB, CB, CG, Exer. |
Hamner 2007 |
135 |
∆ Volume |
-13% |
MLD, CG, Exer. |
Hinrichs 2004 |
14 |
∆ Volume LL |
-60% |
MLD, CB, CG, Exer. |
Karadibak 2008 |
62 |
∆ Volume |
-26% |
MLD, CG, Exer. |
Ko 1998 |
299 |
∆ Volume |
-59 to -68% |
MLD, CB, CG, Exer. |
Szuba 2000 |
40 |
∆ Volume |
-38 to -44% |
MLD, CB, CG, Exer. |
Vignes 2006 |
537 |
∆ Volume |
-30% |
MLD. CB, CG, Exer. |
Wozniewski 2001 |
208 |
∆ Volume |
-19 to -43% |
MLD, CG, Exer. (+IPC) |
Yamamoto 2007 |
82 |
∆ Volume |
-59 to -73% |
2-Phase CDT |
Value of Repeated Intensive Course of Treatment
Prevention of Lymphedema
Initiation and Termination of Lymphedema Treatment
Lymphedema of the Head and Neck and Trunk
Intermittent Sequential Pneumatic Pumps
Lymphedema Treatment Provider Qualifications
Summation
The conclusions of the Technology Assessment are in essential agreement with the others performed over the last decade. Although there is a lack of high-level evidence in support of the de facto lymphedema treatment protocol of complex decongestive therapy, this multi-modal multi-phasic treatment has been found to be effective in treating tens of thousands of patients in the U.S., Europe and Australia over the last 50 years. It is important for Medicare to cover a variety of measurement and treatment modalities and to allow the treating physicians and treating therapists to determine which combination of modalities are indicated for each patient, to arrive at a written plan of treatment and to select the appropriate measurements to measure progress against that plan.
December 7, 2009